Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Leases (2019 - 2025)

Denali Therapeutics has reported Current Leases over the past 7 years, most recently at $9.2 million for Q3 2025.

  • Quarterly Current Leases rose 14.04% to $9.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Sep 2025, up 14.04% year-over-year, with the annual reading at $8.3 million for FY2024, 14.44% up from the prior year.
  • Current Leases was $9.2 million for Q3 2025 at Denali Therapeutics, up from $8.9 million in the prior quarter.
  • Over five years, Current Leases peaked at $9.2 million in Q3 2025 and troughed at $4.9 million in Q1 2021.
  • The 5-year median for Current Leases is $7.1 million (2022), against an average of $7.0 million.
  • Year-over-year, Current Leases soared 34.58% in 2022 and then dropped 0.79% in 2023.
  • A 5-year view of Current Leases shows it stood at $5.5 million in 2021, then soared by 34.2% to $7.3 million in 2022, then fell by 0.79% to $7.3 million in 2023, then rose by 14.44% to $8.3 million in 2024, then increased by 10.3% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Current Leases are $9.2 million (Q3 2025), $8.9 million (Q2 2025), and $8.6 million (Q1 2025).